Chemomab Therapeutics Ltd reports results for the quarter ended in June - Earnings Summary

Chemomab Therapeutics

21/08/2024 13:01

* Chemomab Therapeutics Ltd  CMMB.OQ  reported a quarterly
adjusted loss of 26 cents​​ per share for the quarter ended in
June.  The mean expectation of two analysts for the quarter was
for a loss of one cent per share.  -1 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Chemomab Therapeutics Ltd's reported EPS for the quarter
was a
loss of 26 cents​.
    * The company reported a quarterly loss of $3.63 million.
    * Chemomab Therapeutics Ltd shares had risen by 35.9% this
quarter and gained 143.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 14.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Chemomab
Therapeutics Ltd is $9.00 
This summary was machine generated from LSEG data August 21 at
12:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.01          -0.26          Missed
                                  -0.34